Grifols (GRFS) Other Operating Expenses (2010 - 2019)
Grifols (GRFS) posted Other Operating Expenses of -$351.5 million for Q1 2020, up 64.6% quarter-over-quarter from -$993.1 million in Q4 2019, and down 4.15% year-on-year from -$366.8 million in Q2 2019.
Grifols (GRFS) Other Operating Expenses (2010 - 2019) Analysis & Trends
Grifols (GRFS) has reported Other Operating Expenses for 9 consecutive years, with -$351.5 million the latest figure, recorded in Q1 2020.
- Other Operating Expenses for Q1 2020 came in at -$351.5 million, down 4.15% year-over-year; the trailing twelve-month figure through Dec 2021 was -$351.5 million (up 73.85% YoY), and the FY2025 annual result was -$0.0, changed N/A from the prior year.
- Other Operating Expenses was -$351.5 million for Q1 2020 at Grifols, up from -$993.1 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $0.0 in Q3 2016 and troughed at -$993.1 million in Q4 2019.
- Average Other Operating Expenses over 5 years is -$459.5 million, with a median of -$337.5 million recorded in 2019.
- Year-over-year, Other Operating Expenses plunged 4.1090625028680595e+17% in 2017 and increased 11.63% in 2018.
- Over 5 years, Other Operating Expenses stood at -$0.0 in 2016, then slumped by 4.1090625028680595e+17% to -$979.7 million in 2017, then climbed by 11.63% to -$865.8 million in 2018, then fell by 14.7% to -$993.1 million in 2019, then soared by 64.6% to -$351.5 million in 2020.
- Per Business Quant data, the three most recent Other Operating Expenses figures were -$351.5 million in Q1 2020, -$993.1 million in Q4 2019, and -$337.5 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -993.06 Mn |
| Dec 31, 2018 | -865.76 Mn |
| Dec 31, 2017 | -979.68 Mn |
| Dec 31, 2016 | 0.00 |
| Dec 31, 2013 | 0.00 |
| Jun 30, 2012 | 1.01 Mn |
| Mar 31, 2012 | 135,065.50 |
| Dec 31, 2011 | 60.18 Mn |
| Sep 30, 2011 | 10.72 Mn |
| Jun 30, 2011 | -430,948.46 |
| Mar 31, 2011 | 422,558.32 |
| Sep 30, 2010 | 570,742.50 |